scholarly journals Delayed Bladder Perforation Related to Immediate Single Dose Intravesical Doxorubicin Instillation After TURBT: A Case Report and Literature Review

2021 ◽  
Vol 14 ◽  
pp. 117954762098615 ◽  
Author(s):  
Adel Alrabadi ◽  
Mohannad Abuhamad ◽  
Hammam Mansi ◽  
Sohaib Alhamss ◽  
Nadwa Bustami ◽  
...  
Keyword(s):  
Single Dose ◽  
Unusual Case ◽  
Tumor Resection ◽  
Bladder Perforation ◽  
Muscle Invasive Bladder Cancer ◽  
Case Presentation ◽  
Life Threatening ◽  
Muscle Invasive ◽  
High Index Of Suspicion ◽  
Surgical Treatments

Introduction: Intravesical chemotherapy instillation immediately after tumor resection is a well-known practice in the management of non-muscle invasive bladder cancer. Despite being largely well tolerated in most cases, it is not devoid of severe and life-threatening complications. Case Presentation: We present an unusual case of bladder perforation that happened 2 weeks after bladder tumor resection. The patient had received single dose intra-vesical instillation of doxorubicin after TUR-BT. Conservative managements failed to achieve bladder healing; as a result, open surgical repair was performed. To the best of our knowledge, this is the first reported case of bladder perforation after intra-vesical doxorubicin instillation. Conclusion: The occurrence of such a rare serious complication in a mostly safe intervention must be taken into consideration. A high index of suspicion, timely management, and proceeding to more invasive surgical treatments when necessary are cornerstones in the management and preserving the bladder.

Systemic infection following intravesical therapy with BCG

2021 ◽  
Vol 14 (11) ◽  
pp. e243641
Author(s):  
Ana Andrade Oliveira ◽  
Joana Morais ◽  
Jorge Ribeiro ◽  
Paulo Ferreira Gouveia
Keyword(s):  
Bladder Cancer ◽  
Systemic Infection ◽  
Severe Case ◽  
Invasive Bladder Cancer ◽  
Intravesical Therapy ◽  
Muscle Invasive Bladder Cancer ◽  
Laboratory Confirmation ◽  
Life Threatening ◽  
Muscle Invasive ◽  
High Index Of Suspicion

Immunotherapy with BCG is an effective and widely used treatment for non-muscle-invasive bladder cancer. BCG sepsis is a rare but life-threatening and frequently not a straightforward complication of this treatment; in cases with a high index of suspicion, anti-bacillary treatment should not wait for laboratory confirmation and be instituted immediately. We report a severe case of BCG sepsis, in which timely diagnosis and initiation of antituberculosis agents enabled a full recovery.

Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: A convenient alternative to 5-fluorouracil

2020 ◽  
Vol 150 ◽  
pp. 275-280 ◽  
Author(s):  
Charlotte S. Voskuilen ◽  
Maaike W. van de Kamp ◽  
Nannet Schuring ◽  
Laura S. Mertens ◽  
Arjen Noordzij ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Single Dose ◽  
Mitomycin C ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Systemic Absorption and Pharmacokinetics of Single-dose Early Intravesical Mitomycin C After Transurethral Resection of Non-muscle-invasive Bladder Cancer

Urology ◽  
2013 ◽  
Vol 82 (2) ◽  
pp. 400-404 ◽  
Author(s):  
Massimo Maffezzini ◽  
Fabio Campodonico ◽  
Egi E. Manuputty ◽  
Matteo Puntoni ◽  
Antonietta Martelli ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Single Dose ◽  
Mitomycin C ◽  
Transurethral Resection ◽  
Invasive Bladder Cancer ◽  
Systemic Absorption ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

scholarly journals Recent Advances in the Management of Patients with Non-Muscle-Invasive Bladder Cancer Using a Multidisciplinary Approach: Practical Recommendations from the Spanish Oncology Genitourinary (SOGUG) Working Group

Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4762
Author(s):  
José Rubio-Briones ◽  
Ferran Algaba ◽  
Enrique Gallardo ◽  
José Marcos-Rodríguez ◽  
Miguel Climent ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Working Group ◽  
Time Window ◽  
Tumor Resection ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
State Of Research ◽  
Muscle Invasive ◽  
Definition Of ◽  
Patient At Risk

On the basis of the discussion of the current state of research on relevant topics of non-muscle-invasive bladder cancer (NMIBC) among a group of experts of the Spanish Oncology Genitourinary (SOGUG) Working Group, recommendations were proposed to overcome the challenges posed by the management of NMIBC in clinical practice. A unified definition of the term ‘microhematuria’ and the profile of the patient at risk are needed. Establishing a ‘hematuria clinic’ would contribute to a centralized and more efficient evaluation of patients with this clinical sign. Second or repeated transurethral resection (re-TUR) needs to be defined, including the time window after the first procedure within which re-TUR should be performed. Complete tumor resection is mandatory when feasible, with specification of the presence or absence of muscle. Budding should be used as a classification system, and stratification of T1 tumors especially in extensive and deep tumors, is advisable. The percentage of the high-grade component should always be reported, and, in multiple tumors, grades should be reported separately. Luminal and basal subtypes can be identified because of possibly different clinical outcomes. Molecular subtypes and immunotherapy are incorporated in the management of muscle-invasive bladder cancer but data on NMIBC are still preliminary.

scholarly journals Radiotherapy concurrent with weekly gemcitabine after transurethral tumor resection in muscle ınvasive bladder cancer

2015 ◽  
Vol 11 (4) ◽  
pp. 704 ◽  
Author(s):  
HavvaYesil Cinkir ◽  
Umut Demirci ◽  
Omer Dızdar ◽  
MFaik Cetindag ◽  
Serkan Altınova ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Tumor Resection ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

scholarly journals Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Jianglei Zhang ◽  
Miao Li ◽  
Ze Chen ◽  
Jun OuYang ◽  
Zhixin Ling
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Recurrence Rate ◽  
Tumor Recurrence ◽  
Adverse Reactions ◽  
Tumor Resection ◽  
Intravesical Chemotherapy ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Epirubicin, gemcitabine, and pirarubicin are widely used as first-line drugs for intravesical chemotherapy to prevent tumor recurrence after transurethral bladder tumor resection for non-muscle-invasive bladder cancer (NMIBC). However, which drug is better is less discussed. A total of 335 NMIBC patients administered intravesical chemotherapy underwent transurethral bladder tumor resection (TURBT) in our hospital from October 2015 to October 2019. After TURBT, all the patients received standard intravesical chemotherapy. Through clinical data collection and telephone follow-up, the tumor recurrence and adverse reactions of all patients after bladder perfusion treatment were counted. Recurrence was defined as new tumor appearance in the bladder. Of the 335 patients who underwent intravesical chemotherapy, 109 patients received epirubicin and 114 patients and 112 patients were given gemcitabine and pirarubicin, respectively. According to the general information of the patients, the patients were divided into intermediate-risk and high-risk bladder cancer and compared separately. There was no statistical difference in clinical and pathological features between different groups ( P > 0.05 ). The recurrence rate of intermediate-risk bladder cancer patients shows no difference between three groups ( P > 0.05 ). As for the high-risk bladder cancer patients, it is found that the 1-year recurrence rate between three groups was not statistically significant ( P > 0.05 ), whereas the 2-year recurrence rate of patients given gemcitabine (9.87%) was significantly lower than that of epirubicin (25.37%) and pirarubicin (24.32%), and the difference was statistically significant ( P < 0.017 , Bonferroni adjusted P value). The Kaplan–Meier survival curves showed that the recurrence-free survival rate of patients received gemcitabine was significantly higher than that of the other two groups. Comparing the incidence of adverse reactions during the infusion of the three groups of patients, the differences were not statistically significant ( P > 0.05 ). In patients with high-risk non-muscle-invasive bladder cancer, the application of gemcitabine intravesical chemotherapy is related with a relatively lower recurrence rate but similar incidence of adverse reactions.

Fulminant Septicemia from Aeromonas hydrophilia in a Nonmobile Diabetic Patient

2018 ◽  
Vol 108 (5) ◽  
pp. 405-408
Author(s):  
Sara E. Lewis ◽  
Devin W. Collins ◽  
Adam M. Bressler
Keyword(s):  
Diabetic Patient ◽  
Unusual Case ◽  
Well Water ◽  
Aquatic Environments ◽  
Serious Infection ◽  
Patients At Risk ◽  
Aeromonas Hydrophilia ◽  
Life Threatening ◽  
High Index Of Suspicion ◽  
Portal Of Entry

We report an unusual case of Aeromonas hydrophilia septicemia in a nonmobile diabetic patient secondary to contaminated well water used for bathing with a portal of entry through chronic forefoot and heel ulcers. To date, there are no documented cases similar to this patient's presentation. Aeromonas hydrophilia is commonly distributed among aquatic environments and tends to be found during warmer months. It is a rare cause of disease but can be life threatening and deadly, as in our case, in immunocompromised individuals. As podiatric physicians, we must remain diligent and have a high index of suspicion to identify patients at risk for this rare but serious infection and administer treatment aggressively to limit morbidity and mortality.

Sign in / Sign up

Export Citation Format

Share Document